Research Activity – Page 19

Roche Advances Prasinezumab Into Phase III Trials for Parkinson’s Despite Mixed Phase II Results

5 months ago talkbio0Tagged alpha-synuclein antibody, Biological Markers, Clinical Trials, disease-modifying treatment, PADOVA study, Parkinson 's disease, Pasadena, Phase 3 Clinical Trials, Prasinezumab, Prothena, Roche (company)

Roche; prasinezumab; Parkinson’s disease; Phase III trial; clinical trials; alpha-synuclein antibody; Prothena; PADOVA study; PASADENA study; biomarker; disease-modifying treatment

Illuminating the CKD Patient Journey: Clinicogenomic Data Reshapes Research & Drug Discovery

5 months ago talkbio0Tagged Cell Therapy, Chronic Kidney Diseases, Clinical Trials, clinicogenomics, Drug Discovery, gene therapy, Precision Medicine

chronic kidney disease; CKD; clinicogenomics; drug discovery; cell therapy; gene therapy; clinical trials; personalized medicine

AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China

5 months ago talkbio0Tagged Artificial Intelligence, AstraZeneca, China, Chronic disease, Dosage Forms, Drug Discovery, GZMH gene, Investments, oral therapies, Partnership, R&D, research

AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

5 months ago talkbio0Tagged Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

5 months ago talkbio0Tagged CAR-T therapy, CD19 Antigens, CD20 Antigens, Clinical Trials, dual-targeting, Early-stage, Frequency of Responses, J&J, JNJ-4496, Lymphoma, Phase 1b, relapsed/refractory large-B-cell lymphoma

J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

5 months ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

FDA Approves UroGen’s Chemo-Turned-Gel Drug ZUSDURI Despite Negative Advisory Vote

5 months ago talkbio0Tagged AdComm vote, Approved, chemo-turned-gel drug, Clinical Trials, ENVISION, intermediate-risk, low-grade, mitomycin, muscle-invasive bladder cancer, Negative, NON Mouse, ODAC, Sustained-release Mitomycin C Hydrogel Formulation UGN-102, United States Food and Drug Administration, UroGen, ZUSDURI

UroGen; FDA approval; ZUSDURI; UGN-102; chemo-turned-gel drug; mitomycin gel; low-grade intermediate-risk non–muscle-invasive bladder cancer; negative AdComm vote; ENVISION trial; ODAC

Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs

5 months ago talkbio0Tagged cardiometabolic disease, Deep Apple, Drug Discovery, G-Protein-Coupled Receptors, Non-Incretin, Nordisk, Obesity, research collaboration, Small Molecule

Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery